Opioid Use Disorder Market Research Report - Segmented By Drug (Buprenorphine [Sublocade, Belbuca, Suboxone, Zubsolv], Methadone, Naltrexone), By Route of Administration (Intravenous, Oral), By Age (19 to 40, 41 to 60, and 61 & over) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies); and Region- Size, Share, Growth Analysis | Forecast (2024 2030)

Opioid Use Disorder Market Overview (2024 – 2030)

The global market for Opioid Use Disorder (OUD) was valued at an estimated USD 3.21 billion in 2023 and is anticipated to achieve a valuation of USD 6.54 billion by 2030, registering a Compound Annual Growth Rate (CAGR) of 10.7% throughout the forecast period spanning 2024 to 2030.

OPIOID USE DISORDER

Opioids, designed for pain management, exhibit adverse effects on the central nervous system and analgesic functions, often leading to euphoria. Opioid use disorder manifests as a chronic, recurring condition associated with significantly elevated morbidity and mortality rates. The market's trajectory is propelled by the escalating number of individuals grappling with opioid-related addictions, augmented governmental initiatives, and heightened support from non-governmental organizations (NGOs) and agencies. Nevertheless, impediments such as individuals' reluctance to pursue treatment modalities and the discontinuation of behavioral treatments leading to relapse act as constraints to market growth. Governmental programs and funding play pivotal roles in sustaining this industry.

Key Market Insights:

Orexo AB has entered into a collaboration with ApexB.io and Magellan Rx Management to explore the utilization of Modia, a digital therapy tailored for individuals with Opioid Use Disorder (OUD). Modia facilitates personalized, interactive psychotherapy sessions accessible to individuals with OUD via their computer or mobile devices.

The acquisition of Opiant Pharmaceuticals, Inc. by Indivior PLC has been successfully concluded, enhancing Indivior's position in the addiction therapy domain, particularly with the investigational opioid overdose therapy candidate OPNT003.

Global Opioid Use Disorder Market Drivers:

Growing Recognition of Buprenorphine Patches as a Successful Treatment Approach to Drive Market Expansion:

There is a growing demand for patches addressing opioid addiction, recognized as an effective therapeutic for opioid use disorder. Transdermal patches, offering benefits such as self-administration and improved medication administration mechanisms, are gaining acceptance. Collaborations, such as the one between WellSpan Health and York Opioid Collaborative in 2009, are anticipated to accelerate therapy acceptance, with a projected influx of new patients driving global market expansion.

Increasing Cases of Opioid Addiction to Increase Market Share:

The global prevalence of severe and chronic illnesses, leading to opioid use for pain management, contributes to the rise in opioid addiction cases. The growing frequency of Opioid Use Disorder (OUD) globally, as evidenced by reports such as the CDC's estimation of 2.7 million individuals aged 12 or older with OUD in the United States in 2021, presents a significant market expansion opportunity.

Global Opioid Use Disorder Market Challenges:

Adverse OUD Drug Effects to Limit Market Growth:

Challenges are anticipated due to the negative effects associated with medications treating opioid addiction, including muscular pains, nausea, respiratory issues, and psychological concerns. Regulatory warnings, such as the U.S. FDA's cautionary statement on dental issues linked to buprenorphine, might hinder market growth to some extent.

Global Opioid Use Disorder Market Opportunities:

Governmental and non-governmental organizations emphasizing awareness campaigns represent a key opportunity for industry growth. The increased involvement of such organizations, exemplified by initiatives like Health and Human Services' funding for drug abuse prevention and treatment, is expected to encourage individuals with opioid-related issues to seek treatment, thus benefiting the global market in the foreseeable future.

Global Opioid Use Disorder Market Segmentation: By Drug

• Buprenorphine
• Sublocade
• Belbuca
• Suboxone
• Zubsolv
• Methadone
• Naltrexone

The drug class-based segmentation categorizes the market into methadone, buprenorphine, and naltrexone. In 2022, the buprenorphine market category secured the highest market share at 36%. This dominance is attributed to numerous branded medications within this category, particularly prevalent in developed markets such as the U.S. and France. Notable buprenorphine medications include SUBLOCADE, SUBOXONE, and ZUBSOLV. Projected growth rates suggest a slower expansion for the methadone market, around 23%, due to an increase in generic product launches and a limited number of new product introductions. The naltrexone sector is expected to have a smaller market share over the projection period, driven by a scarcity of product options.

Global Opioid Use Disorder Market Segmentation: By Route of Administration

• Intravenous
• Oral

Based on the route of administration, the market is segmented into oral and parenteral categories. The parenteral segment is anticipated to command the largest market share, approximately 53%, owing to the availability of various OUD medications in parenteral form with diverse dosages. This trend underscores the continued dominance of parenteral medication delivery in the market. Although the global market share for oral medications is expected to decline, there is a simultaneous anticipated rise due to the preference for oral administration among a significant portion of the population.

Global Opioid Use Disorder Market Segmentation: By Age

• 19 to 40
• 41 to 60
• 61 & over

Market segments are defined by age groups, including 19 to 40, 41 to 60, and 61 and older. The 19 to 40 age group led the market in 2022, holding a market share of 42%, driven by changing living patterns and increased opioid use among young and middle-aged individuals. This trend is expected to persist during the projection period.

Global Opioid Use Disorder Market Segmentation: By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies

Distribution channels are categorized into hospital pharmacies, retail pharmacies & stores, and online pharmacies. The hospital pharmacy sector is projected to dominate the global market with a share of 39%, mainly due to the patient population's reliance on this channel for parenteral OUD medications like buprenorphine. Retail pharmacies & stores are expected to be the second-largest segment, driven by the dependence of the patient population on these outlets for prescription fulfillment. The internet pharmacy market is predicted to experience the highest compound annual growth rate (CAGR) as more patients opt for online platforms for medication procurement.

Global Opioid Use Disorder Market Segmentation: By Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

North America is anticipated to dominate the market with a projected share of 45%, owing to a significant portion of the population suffering from opioid dependence, the presence of key industry players, and increased government involvement in addressing the issue. Europe is expected to secure the second position globally, driven by new product releases and a rising number of patients with opioid dependence. The Asia Pacific market is projected to exhibit the highest CAGR, supported by increased public awareness of the disease and rising healthcare spending. Other regions, such as South America, the Middle East, and Africa, are expected to witness market expansion due to the growing number of patients with opioid dependence, increased healthcare costs, and heightened public awareness.

COVID-19 Impact on Global Opioid Use Disorder Market:

The COVID-19 epidemic is anticipated to have a conflicting impact on the OIJD market. The strain on the global healthcare system led to a decline in elective procedures in 2020, impacting the prevalence of OUD. While opioid use for pain management was expected to decrease, the cancellation of doctor's appointments during the pandemic resulted in a rise in long-term opioid use, subsequently increasing OUD cases. Although there was not a significant increase in new opioid users, the market grew as existing users continued their drug consumption.

Global Opioid Use Disorder Market Recent Developments:

Opioids, a class of medications used for pain relief, muscle relaxation, and tension relief, play a crucial role in the market. Opioid use disorder (OUD) is a chronic, relapsing brain disease characterized by excessive opioid use despite negative side effects. The market is expected to grow due to increasing opioid prescriptions, heightened OUD awareness, government initiatives for identification and treatment, and approvals for OIJD treatment medications. Notable recent developments include the approval of Subutex by the Swedish Medical Products Agency in May 2020.

• In June 2022, Titan Pharmaceuticals, Inc. partnered with Indegene to enhance their multichannel digital marketing strategy in the United States, aiming to improve the delivery of Probuphine implants for individuals struggling with opioid addiction.
• In April 2024, the New York State Department of Health (DOH) and New York State Office of Addiction Services and Supports (OASAS) introduced the Buprenorphine Assistance Pilot Programme to assist in covering the expenses of buprenorphine for OUD treatment.